News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com
June 23, 2021
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 11, 2021
COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences
June 03, 2021
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
May 13, 2021
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
April 30, 2021
COMPASS Pathways announces pricing of public offering
April 27, 2021
COMPASS Pathways launches proposed public offering
April 15, 2021
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
April 12, 2021
COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
April 01, 2021
COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors
March 23, 2021
COMPASS Pathways granted two US patents
March 09, 2021
Our annual review, with a letter to our shareholders and some highlights from our year
March 02, 2021
COMPASS Pathways plc to announce fourth quarter and full year end results
March 01, 2021
COMPASS Pathways plc to participate in Cowen’s 41st Annual Health Care Conference
February 09, 2021
COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientists
February 03, 2021
COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapy
January 28, 2021
COMPASS Pathways plc to participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference
January 08, 2021
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care
January 06, 2021
COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences
December 16, 2020
COMPASS Pathways News | December 2020 Issue
Our highlights in the second half of 2020 as we work towards building a world of mental wellbeing for everyone.
November 12, 2020
COMPASS Pathways plc announces financial results for third quarter 2020
November 09, 2020
COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care
November 05, 2020
COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020
November 04, 2020
COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences
October 26, 2020
COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO
September 22, 2020
COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares
September 18, 2020
COMPASS Pathways announces pricing of upsized initial public offering
July 01, 2020
COMPASS Pathways News | July 2020 Issue
Here are highlights of our activities in the first half of 2020 as we work towards building a world of mental wellbeing for everyone.
June 23, 2020
COMPASS Pathways strengthens leadership team with appointment of Trevor Mill as Chief Development Officer
April 27, 2020
COMPASS Pathways concludes successful Series B investment round
Announcement of our successful $80m Series B investment round completion.